RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts

New clinical data show AI-driven gains in aneurysm growth detection, stroke interpretation accuracy, and radiology workflow efficiency across enterprise imaging environments.

SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced details of 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, held February 4-6, at the Ernest N. Morial Convention Center in New Orleans. The abstracts span aneurysm monitoring, ischemic stroke detection, advanced imaging visualization, and radiology workflow optimization. Findings reflect the impact of deep clinical AI delivered through the Rapid Enterprise™ platform, designed to scale across radiology and acute workflows.

The clinical data demonstrate how RapidAI’s clinically validated, FDA-cleared AI solutions can improve diagnostic performance, reduce interpretation time, and deliver measurable efficiency and economic gains for stroke teams and radiology departments. Rapid’s unique approach, called Deep Clinical AI, delivers real results by providing not just triage notifications but also visualization, localization, characterization, and tracking changes over time. The following abstracts highlight this approach and will be presented at the time below during ISC. Additional RapidAI abstract descriptions accepted by ISC can be found here.

Date: February 5, 2026
Time: 12:30–2:30 p.m. CT
Location: Hall B, Poster Hall

Artificial Intelligence Augments Radiologists Capabilities in Tracking Aneurysm Growth Over Time

• The abstract evaluated longitudinal aneurysm measurements using RapidAI’s Aneurysm platform and compared them with neuroradiologists' interpretations.
• Rapid detected 46% more clinically significant growth compared with neuroradiologists alone (27/28 incidents of aneurysm growth detected by Rapid vs. 14/28 aneurysms for neuroradiologists alone).
• The findings indicate that RapidAI’s Aneurysm platform reliably captures true linear growth while maintaining comparable specificity, supporting improved longitudinal monitoring and assessment of rupture risk, and potentially enabling earlier, life-saving interventions.

“Identifying true aneurysm growth over time is challenging, even for highly experienced neuroradiologists,” said Lead Author Jeremy Heit, MD, PhD. “Our findings suggest that deep clinical AI can serve as a valuable adjunct by consistently detecting subtle changes that are difficult to discern visually, helping support longitudinal assessment and more informed decision-making aimed at preventing aneurysm rupture and stroke.”

Reduced Interpretation Time, Improved Detection Accuracy of High-Grade Stenosis and Occlusions using Lumina 3D: A Multi-Reader, Multi-Case Study

• The study assessed the impact of Lumina 3D, Rapid’s automated 3D head-and-neck reconstructions, on stroke occlusion and stenosis detection and interpretation time.
• Across 20 cases involving 24 occlusions and 11 stenoses, diagnostic accuracy improved from 76.1% without Lumina 3D to 85.6% with Lumina 3D, a 9% improvement (p = 0.0004).
• Interpretation time decreased by an average of 34 seconds per case (p<0.05), with general radiologists achieving time savings of more than 1 minute per case.
• The study concludes that Lumina 3D can enhance stroke workflows by enabling faster and more accurate identification of clinically significant stroke findings, potentially enabling faster interventions and better outcomes for stroke patients.

Improving Efficiency and CT Technologists’ Workflow using Lumina 3D, an AI-Enhanced CT Head and Neck Reconstruction Solution

• With the shortage of CT techs nationwide, time savings and efficiency is increasingly important for diagnostic centers to keep up with the increase in imaging demands.
• Abstract evaluating operational performance of CT techs before and after the implementation of Lumina 3D.
• Prior to deployment, manual reconstructions averaged 31 minutes per patient. Following implementation, automated reconstructions required 7 minutes, resulting in a 77.4% reduction in technologist time, or 24 minutes saved per image.
• Based on monthly CTA volumes, the time savings translated to approximately 81.6 hours saved per month, enabling 108 additional scans and generating an estimated $43,000 in additional monthly imaging revenue. The results demonstrate how AI-driven automation can expand imaging capacity while reducing staff workload.

“These ISC abstracts reflect the depth and rigor of the clinical evidence supporting our unique solutions,” said Karim Karti, Chief Executive Officer of RapidAI, “Together, these studies demonstrate the power of deep clinical AI when it is seamlessly integrated across radiology and care team workflows and built on an enterprise-grade platform. Proof matters in AI, and these data show meaningful gains in diagnostic confidence and operational efficiency with RapidAI.”

In addition, RapidAI will be highlighting three abstracts based on data from its collaboration with the Florida Stroke Registry. The Registry consists of 190 stroke centers and hospitals across the state of Florida. Data from these centers is reported to the Registry and analyzed alongside RapidAI imaging metrics to help identify innovative ways to improve stroke care for Florida patients. Abstracts from this partnership highlight the importance of real-world stroke research in improving clinical understanding and patient outcomes.

The International Stroke Conference is the world’s leading meeting focused on the science and treatment of cerebrovascular disease, bringing together clinicians, researchers, and healthcare leaders from around the globe.

About RapidAI

RapidAI is the trusted leader in deep clinical AI, helping hospitals deliver faster, more informed care through intelligent imaging and integrated workflows. The Rapid Enterprise™ Platform supports disease states across the care spectrum, but it’s our clinical depth that drives the most meaningful impact—improving decision-making, patient outcomes, and health system performance.

Used by more than 2,500 hospitals in over 100 countries and backed by 700+ clinical studies, including research that helped expand national stroke-treatment guidelines, RapidAI is the most clinically validated and widely deployed clinical AI platform in the world.

Discover the value of clinical depth at scale at rapidai.com.